Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 14, 2024

SELL
$4.64 - $9.56 $10.6 Million - $21.8 Million
-2,277,689 Reduced 99.85%
3,423 $22,000
Q3 2023

Nov 14, 2023

SELL
$9.4 - $14.04 $897,183 - $1.34 Million
-95,445 Reduced 4.02%
2,281,112 $21.5 Million
Q2 2023

Aug 14, 2023

BUY
$12.96 - $20.93 $1.35 Million - $2.18 Million
104,363 Added 4.59%
2,376,557 $33.2 Million
Q1 2023

May 05, 2023

BUY
$13.48 - $18.79 $1.46 Million - $2.03 Million
108,165 Added 5.0%
2,272,194 $42.6 Million
Q4 2022

Feb 14, 2023

BUY
$12.61 - $18.74 $703,259 - $1.05 Million
55,770 Added 2.65%
2,164,029 $29.8 Million
Q3 2022

Nov 14, 2022

BUY
$15.33 - $20.36 $849,925 - $1.13 Million
55,442 Added 2.7%
2,108,259 $40.3 Million
Q2 2022

Aug 15, 2022

SELL
$11.63 - $21.55 $1.5 Million - $2.78 Million
-129,213 Reduced 5.92%
2,052,817 $31.3 Million
Q1 2022

May 13, 2022

BUY
$16.63 - $27.73 $1.31 Million - $2.18 Million
78,640 Added 3.74%
2,182,030 $44.4 Million
Q4 2021

Feb 11, 2022

SELL
$20.7 - $34.18 $2.24 Million - $3.7 Million
-108,170 Reduced 4.89%
2,103,390 $61.4 Million
Q3 2021

Nov 15, 2021

BUY
$19.05 - $28.32 $4.63 Million - $6.89 Million
243,241 Added 12.36%
2,211,560 $47.7 Million
Q2 2021

Aug 16, 2021

SELL
$18.93 - $25.65 $672,847 - $911,703
-35,544 Reduced 1.77%
1,968,319 $50.5 Million
Q1 2021

May 17, 2021

BUY
$11.86 - $21.77 $17 Million - $31.2 Million
1,433,071 Added 251.07%
2,003,863 $36.5 Million
Q4 2020

Feb 12, 2021

BUY
$7.25 - $11.76 $1.23 Million - $1.99 Million
169,219 Added 42.14%
570,792 $6.59 Million
Q3 2020

Nov 16, 2020

BUY
$6.53 - $8.6 $2.62 Million - $3.45 Million
401,573 New
401,573 $3.06 Million

Others Institutions Holding CDMO

About Avid Bioservices, Inc.


  • Ticker CDMO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 62,167,500
  • Market Cap $772M
  • Description
  • Avid Bioservices, Inc., a contract development and manufacturing organization, provides process development and current good manufacturing practices (CGMP) clinical and commercial manufacturing services focused on biopharmaceutical drug substances derived from mammalian cell culture. The company produces monoclonal antibodies and recombinant pro...
More about CDMO
Track This Portfolio

Track Ranger Investment Management, L.P. Portfolio

Follow Ranger Investment Management, L.P. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ranger Investment Management, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Ranger Investment Management, L.P. with notifications on news.